Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501106 | 0.89 | POLB (0.36) | CCNE1CDK2ALDH1A1MEN1KMT2A | |
| SCHEMBL4752791 | 0.73 | — | — | |
| SCHEMBL5578043 | 0.72 | — | — | |
| SCHEMBL13502540 | 0.56 | ALOX15 (0.59) | ALDH1A1MEN1KMT2A | |
| SCHEMBL10515566 | 0.54 | LTA4H (0.46) | ESR1ESR2ALDH1A1MEN1KMT2A | |
| SCHEMBL9159542 | 0.53 | MEN1 (0.62) | ESR1ESR2ALDH1A1MEN1KMT2A | |
| SCHEMBL21156724 | 0.53 | KMT2A (0.51) | ESR1ALDH1A1MEN1KMT2A | |
| Hydroquinone SCHEMBL9578965 | 0.53 | CA2 (0.58) | ESR1ESR2ALDH1A1MEN1KMT2A | |
| Hydroquinone SCHEMBL8749725 | 0.53 | CA2 (0.57) | ESR1ESR2ALDH1A1MEN1KMT2A | |
| Hydroquinone SCHEMBL10535422 | 0.53 | CA2 (0.58) | ESR1ESR2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1713814-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | STRUCTURAL GENOMIX (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068473-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | MAP3K20, MAP4K2, MAP4K3 | CCNE2 3086/4885CCNE1 1947/4885CDK2 110/4885 |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | MAP3K20, MAP4K2, MAP4K3 | CCNE2 3086/4885CCNE1 1947/4885CDK2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.